Clinical Data on TetraLogic Pharmaceuticals’ Smac Mimetic Birinapant to be Presented at American Society of Clinical Oncology

Published: May 22, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

TetraLogic Pharmaceuticals, a biopharmaceutical company developing novel small molecule Smac mimetic drugs to treat cancer, today announced that data from two clinical studies investigating its lead Smac mimetic drug candidate birinapant (formerly TL32711) will be presented at the 2013 Annual Meeting of the American Society of Clinical Oncology (ASCO) being held May 31 – June 4, 2013 in Chicago, IL. Birinapant is in clinical trials for solid tumors and hematological malignancies.

Help employers find you! Check out all the jobs and post your resume.

Back to news